Please login to the form below

Not currently logged in
Email:
Password:

Celgene sets up stem cell deal with Mesoblast

Oncology drug specialist hoping to tap into possible treatments for Crohn's and cancer

Celgene 

Celgene is spending $45m to buy a minority stake into the Australian stem cell drug manufacturer Mesoblast. 

The Sydney-based firm's shares jumped 24% - higher than at any time in the past decade - as it agreed to sell a minority stake to US-based oncology specialist Celgene for A$58.5m ($45m).

This would mean that Celgene would be purchasing about 4.5% of Mesoblast.

Celgene, which markets the multiple myeloma drug Revlimid, will gain a six-month right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological ailments.

“They are a world leader in immunology and oncology with very strong franchises. It makes sense for some of our leading products in those indications to be potentially partnered with Celgene,” Mesoblast's chief executive Silviu Itescu said. 

“This agreement provides an opportunity for Celgene to add to its leading cellular and regenerative medicine pipeline,” said Celgene's COO Mark Alles.

Mesoblast's chief executive Silviu Itescu, told reporters: “They are a world leader in immunology and oncology with very strong franchises. It makes sense for some of our leading products in those indications to be potentially partnered with Celgene.”

Mesoblast has a number of drug candidates late-stage trials, including one product for treating acute graft versus host disease, a complication that can occur after a stem-cell or bone-marrow transplant, with another is for refractory Crohn's disease. 

Mesoblast already has a number of pharma tie-ups, including with Japanese firm JCR Pharmaceuticals and Israeli generics giant Teva.  

Stem cell research is still in an early stage of development with its potential yet to be fully tapped.

The biotech industry, which is predominately running trials in this area, did receive a boost in February when Europe approved its first stem cell derived treatment.

The approval was for Chiesi's Holoclar (an ex-vivo expanded autologous human corneal epithelial cells containing stem cells), for moderate to severe limbal stem cell deficiency (LSCD) due to physical or chemical burns to the eye(s) in adults.

Article by
Ben Adams

14th April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics